- Dipeptidyl-peptidase 4 inhibition and its side effects2011 | First Faculty of Medicine
- Update on therapy with dipeptidyl-peptidase 4 inhibitors2014 | Second Faculty of Medicine
- Sitagliptin2008 | Second Faculty of Medicine
- The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus2016 | First Faculty of Medicine, Third Faculty of Medicine
- Possible effect of OAS1 and TMPRSS6 but not DPP4 and ZNF335 polymorphisms on COVID-19 severity in the Czech population2023 | First Faculty of Medicine, Third Faculty of Medicine
- Annual monitoring of side effects of administering sitagliptin in patients with type 2 diabetes mellitus2016 | First Faculty of Medicine, Third Faculty of Medicine
- Sitagliptin is safe alternative in the treatment of the light renal insuficiency2008 | Second Faculty of Medicine
- Clinical efficacy of sitagliptin and vildagliptin2009 | Second Faculty of Medicine
- Comparison of clinical efficacy of DPP-4 inhibitors sitagliptin and vildagliptin2009 | Second Faculty of Medicine
- Efficiency and safety of linagliptin - relevance to clinical practice2014 | First Faculty of Medicine
- Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights2020 | First Faculty of Medicine
- Early Diagnosis of Pancreatic Adenocarcinoma Role of Stroma, Surface Proteases, and Glucose-Homeostatic Agents2012 | First Faculty of Medicine
- Incretin-based treatment of diabetes and cardiovascular complications2020 | First Faculty of Medicine
- Treatment of diabetes and cardiovascular risk: the end of a dogma in the treatment of type 2 diabetes2016 | First Faculty of Medicine
- Incretin treatment of diabetes2011 | Second Faculty of Medicine
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus2013 | First Faculty of Medicine
- Dulaglutid2016 | Second Faculty of Medicine